Answers are grounded in this paper and cite their sources.
Statin intolerance is a clinical syndrome whereby adverse effects (AEs) associated with statin therapy [most commonly statin-associated muscle symptoms (SAMS)] result in the discontinuation of therapy and consequently increase the risk of adverse cardiovascular outcomes. However, complete statin intolerance occurs in only a small minority of treated patients (estimated prevalence of only 3-5%). Many perceived AEs are misattributed (e.g. physical musculoskeletal injury and inflammatory myopathies), and subjective symptoms occur as a result of the fact that patients expect them to do so when taking medicines (the nocebo/drucebo effect)-what might be truth even for over 50% of all patients with muscle weakness/pain. Clear guidance is necessary to enable the optimal management of plasma in real-world clinical practice in patients who experience subjective AEs. In this Position Paper of the International Lipid Expert Panel (ILEP), we present a step-by-step patient-centred approach to the identification and management of SAMS with a particular focus on strategies to prevent and manage the nocebo/drucebo effect and to improve long-term compliance with lipid-lowering therapy.
No takes yet. Share an insight, caveat, or question.
Penson et al. (2022) conducted a review in Statin-associated muscle symptoms (SAMS) and statin intolerance. Statin therapy / step-by-step management of nocebo/drucebo effect was evaluated. The nocebo/drucebo effect may account for >50% of statin-associated muscle symptoms, whereas complete statin intolerance occurs in only 3-5% of statin-treated patients.
Synapse has enriched 10 related papers. Consider them for comparative context: